Synergistic Analgesic Effect of Salmon Calcitonin Loaded PLGA Nanoparticles – In Vivo Study

Salmon calcitonin (subcutaneous or intranasal) has been shown to have an analgesic effect in individuals suffering from a variety of painful skeletal diseases, including nontraumatic osteoporotic vertebral fractures, in multiple prospective clinical studies.Several assessments have determined that salmon calcitonin is a secure and efficacious option for osteoporosis therapy.The precise process through which calcitonin mitigates pain is not yet understood.It's theorized that there may be specific receptors in the brain for salmon calcitonin, or that alterations in serotonergic descending pathways affecting sensory transmission via C fibers account for calcitonin's pain-relief effects in osteoporotic patients.To study this substance, Salmon Calcitonin attached to PLGA nanoparticles (SC-PLGA NPs) has been developed using dual-emulsion (W/O/W) and solid-oil dipping techniques.The morphology of the particles was analysed by scanning electron microscopy, and their analgesic effectiveness was evaluated in vivo using the tail flick method.Male albino rats with body weights between 160 and 180 grams were used for the study.Nano-sized particles ranging from 400-550 nm, mostly spherical with a limited size variance, have been synthesized.Studies confirmed that PLGA nanoparticles carrying salmon calcitonin effectively diminished pain swiftly.Groups treated with SC-PLGA nanoparticles experienced significant pain relief, confirmed by the tail flick test.Statistical evaluation via the Mann-Whitney test demonstrated that 93.33% of mice that underwent subcutaneous-PLGA nanoparticle treatment exhibited improvements.The creation of these nanoparticles carrying Salmon calcitonin correlates strongly with positive results.